The latest analyst update on BeOne Medicines fine tunes the model fair value estimate from US$408.32 to US$411.51 per share, reflecting incremental shifts in long term assumptions. Recent commentary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results